TrialGynecologic oncology2014

A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Linda R Duska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.